ANORO ELLIPTA (umeclidinium/vilanterol) Patient Assistance Program
Don’t let the high cost of Anoro Ellipta disrupt your COPD treatment. GSK’s patient assistance program provides Anoro free of charge to eligible patients — and GSK now caps out-of-pocket costs at $35 a month for most others. We manage your entire enrollment for a flat $69.95 per month.
- Clear & Transparent Pricing — Applying To GSK Directly Is Always Free
- Paperwork, Documentation & Doctor-Coordination Handled For You
- Comprehensive Support: From Application To Entire Journey
- Authorized-Generic & $35-Cap Guidance — Anoro’s Cost Options Multiplied In 2025
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Anoro Ellipta (Umeclidinium/Vilanterol) Is A Once-Daily Maintenance Inhaler For COPD, Combining A Long-Acting Muscarinic Antagonist And A Long-Acting Beta2-Agonist In One Breath-Activated Device. It Is Not A Rescue Inhaler.
- Retail Prices Run Around $530 Per 30-Day Inhaler — But Since 2025, GSK Caps Out-Of-Pocket Costs For Its U.S. Respiratory Medicines, Including Anoro, At $35 Per Month, And An FDA-Approved Authorized Generic (Prasco) Reached Pharmacies In April 2025.
- The GSK Patient Assistance Program Provides Anoro Free To Patients With Household Income Up To About 300% Of The Federal Poverty Level ($47,880 Single / $99,000 Family Of Four) — Including Medicare Part D Enrollees Who Have Spent $600 On Prescriptions This Year.
- In January 2026, Medicare Selected Anoro Ellipta For Drug Price Negotiation — Roughly 281,000 Medicare Enrollees Use It — With Negotiated Prices Taking Effect In 2028. Until Then, The $2,100 Part D Cap (2026) Limits Annual Costs.
What Is Anoro Ellipta Prescription Assistance Program?
The Anoro Ellipta Patient Assistance Program is run through the GSK Patient Access Programs Foundation and provides Anoro at no medication cost to qualifying patients: U.S. residents with household income up to roughly 300% of the Federal Poverty Level ($47,880 for one person, $64,920 for two, $99,000 for a family of four), covering both the uninsured and Medicare Part D enrollees who have spent at least $600 out of pocket on prescriptions in the current calendar year. Applying directly (1-866-728-4368) is always free. Anoro’s affordability picture got genuinely better in 2025 — GSK’s $35 monthly out-of-pocket cap, an authorized generic, a cash-pay home-delivery option — but more options means more ways to pick the wrong one for your insurance situation. For a flat $69.95 per month, our Patient Advocates check every route — free drug, $35 cap, generic, copay card — and enroll you in the one that costs you least.
Pharmacy Price Comparison
- Without assistance, Anoro Ellipta costs roughly $480–$580 per inhaler. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$555.00 | Save ~$485/inhaler |
| CVS Pharmacy | ~$580.00 | Save ~$510/inhaler |
| Walmart | ~$510.00 | Save ~$440/inhaler |
| Costco | ~$490.00 | Save ~$420/inhaler |
| Kroger | ~$500.00 | Save ~$430/inhaler |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Anoro Ellipta Prescription Program?
The GSK Patient Assistance Program is free to apply for and provides Anoro at no medication cost if approved. Our $69.95/month service covers full advocacy — for patients who want an experienced team sorting the five overlapping cost routes and managing enrollment end-to-end.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Anoro Ellipta:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
- Still $480–$580 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
The GSK Patient Assistance Program publishes clear eligibility rules for free Anoro. You will generally qualify if all of the following are true — and if your situation doesn’t fit neatly, contact AffordMyPrescriptions so we can review your case and determine if you qualify for Anoro assistance:
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Anoro Ellipta Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured Or Underinsured And Cannot Afford Your Medication
- Your Household Income Is At Or Below About 300% Of The Federal Poverty Level — $47,880 (1 Person) Up To $99,000 (Family Of 4)
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Anoro Ellipta:
Anoro Ellipta combines two long-acting bronchodilators — umeclidinium (a LAMA) and vilanterol (a LABA) — in one once-daily inhaler for the maintenance treatment of COPD. The two drugs relax airway muscles through different mechanisms, keeping airways open around the clock.
How Anoro Works:
COPD narrows airways through both muscle constriction and nerve-signal overactivity. Umeclidinium blocks the muscarinic receptors that trigger airway tightening, while vilanterol stimulates beta2-receptors that actively relax airway muscle — a complementary, dual-bronchodilator approach shown to improve lung function more than either drug alone. Anoro contains no steroid, which distinguishes it from triple-therapy inhalers like Trelegy.
Form and Use:
One inhalation, once daily, at the same time each day, from the Ellipta dry-powder device — each device lasts 30 days. Anoro is maintenance-only: it will not relieve sudden breathlessness, and every patient should also carry a rescue inhaler. Consistency is the entire game in COPD maintenance — skipped months from cost gaps show up as exacerbations and hospital visits, which is why year-round affordability matters more than any single fill’s price.
Generic Availability:
Since April 2025, an FDA-approved authorized generic umeclidinium/vilanterol inhaler (marketed by Prasco) has been available — the identical product without the brand name. Independent generics remain blocked by patents until about 2030. The authorized generic typically prices below brand at the pharmacy counter and is the first thing worth asking your pharmacist about if you’re paying cash.
Warnings:
Anoro should not be used in asthma (LABA monotherapy risk) and is not for acute bronchospasm. Tell your prescriber about heart conditions, narrow-angle glaucoma, prostate or bladder problems (urinary retention risk), and all other inhalers you use — duplicating LAMA or LABA drugs is a common and avoidable error. Report worsening breathing immediately after dosing, palpitations, eye pain, or difficulty urinating.
FAQ (Frequently Asked Questions)
How Much Does Anoro Ellipta Cost Without Insurance?
Retail runs around $530 per 30-day inhaler — roughly $6,400 per year. But uninsured patients have three better routes: the GSK Patient Assistance Program (free if income-eligible), the Prasco authorized generic, and GSK’s cash-pay Direct to You pharmacy. Our $69.95 monthly fee covers finding and enrolling in the cheapest one for you.
What Is GSK’s $35 Monthly Cap?
Since January 2025, GSK caps out-of-pocket costs for its nine U.S. respiratory medicines — including Anoro — at $35 per month for eligible patients. It’s one of the strongest affordability commitments in the inhaler market, and surprisingly few patients have heard of it. We verify your eligibility as part of enrollment.
Does Medicare Cover Anoro?
Yes — under Part D, with the $2,100 annual out-of-pocket cap (2026) limiting total drug spending. Bigger news: CMS selected Anoro in January 2026 for Medicare price negotiation, with negotiated prices effective 2028 — about 281,000 Medicare enrollees use Anoro, and this should cut their costs meaningfully. Until then, the GSK PAP accepts Part D patients who’ve spent $600 on prescriptions this year.
Can I Use The Anoro Coupon With Medicare?
No — the coupon excludes Medicare, and treats everyone 65+ as Medicare-eligible. Medicare patients rely on the Part D cap, Extra Help if income-qualified, or the PAP.
Is Anoro A Rescue Inhaler?
No — it’s once-daily maintenance treatment and will not relieve sudden breathing trouble. You need a separate rescue inhaler (like albuterol), and if you’re using rescue puffs more often, tell your prescriber — it usually means the maintenance regimen needs adjusting, not that you should double up on Anoro.
What If My Application Is Denied?
? Denials are usually about documentation — missing income proof, an insurance-status mismatch, or incomplete prescriber sections. Applications can be corrected and resubmitted — and for Anoro, a denial triggers our fallback check across the generic, the $35 cap, and Direct to You. We review the denial letter, fix what triggered it, and resubmit on your behalf
Take Control of Your Medication Costs
Anoro went from one price to five routes in eighteen months — free drug, $35 cap, authorized generic, coupon, cash-pay direct — with Medicare negotiation arriving in 2028. The right route depends entirely on your situation. Check your eligibility today; the pre-qualification review is free, and if we can’t help you, you pay nothing.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.